Literature DB >> 16246487

Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer.

Alex Lyakhovich1, Jordi Surralles.   

Abstract

An increasing number of studies provide evidences linking disruption of Fanconi anemia/BRCA cascade with sporadic cancers. Given that this pathway plays essential roles in response to the DNA interstrand cross-links, these cancers are expected to be chemosensitive to cross-link based therapy. In the present mini-review we expand the spectrum of possibilities for FA/BRCA disruption and review some works describing functional upstream and downstream events linking disruption of the FA/BRCA pathway to sporadic cancer. This may involve but not limited to epigenetic silencing of the FA-core complex or BRCA1/2, mutations of one or several FA-BRCA genes or modification of encoded products. All this may serve as a platform for occurrence, development and treatment of sporadic cancers and therefore deserves to be in the focus of new research directions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16246487     DOI: 10.1016/j.canlet.2005.07.038

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  28 in total

Review 1.  Fanconi anaemia: from a monogenic disease to sporadic cancer.

Authors:  Antonio Valeri; Sandra Martínez; José A Casado; Juan A Bueren
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

Review 2.  Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy.

Authors:  Yanxin Lu; Yang Liu; Ying Pang; Karel Pacak; Chunzhang Yang
Journal:  Pharmacol Ther       Date:  2018-04-03       Impact factor: 12.310

3.  Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability.

Authors:  Massimo Bogliolo; Alex Lyakhovich; Elsa Callén; Maria Castellà; Enrico Cappelli; María J Ramírez; Amadeu Creus; Ricard Marcos; Reinhard Kalb; Kornelia Neveling; Detlev Schindler; Jordi Surrallés
Journal:  EMBO J       Date:  2007-02-15       Impact factor: 11.598

4.  Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.

Authors:  Wenrui Duan; Li Gao; Weiqiang Zhao; Marino Leon; Wolfgang Sadee; Amy Webb; Kimberly Resnick; Xin Wu; Bhuvaneswari Ramaswamy; David E Cohn; Charles Shapiro; Paul R Andreassen; Gregory A Otterson; Miguel A Villalona-Calero
Journal:  Transl Res       Date:  2012-10-11       Impact factor: 7.012

Review 5.  The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma.

Authors:  Lindsey E Romick-Rosendale; Vivian W Y Lui; Jennifer R Grandis; Susanne I Wells
Journal:  Mutat Res       Date:  2013-01-17       Impact factor: 2.433

6.  Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival.

Authors:  Jill M Wagner; Larry M Karnitz
Journal:  Mol Pharmacol       Date:  2009-04-29       Impact factor: 4.436

Review 7.  Helicases as prospective targets for anti-cancer therapy.

Authors:  Rigu Gupta; Robert M Brosh
Journal:  Anticancer Agents Med Chem       Date:  2008-05       Impact factor: 2.505

Review 8.  Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy.

Authors:  Paul R Andreassen; Keqin Ren
Journal:  Curr Cancer Drug Targets       Date:  2009-02       Impact factor: 3.428

9.  Genome-wide transcriptional analysis of the human cell cycle identifies genes differentially regulated in normal and cancer cells.

Authors:  Ziv Bar-Joseph; Zahava Siegfried; Michael Brandeis; Benedikt Brors; Yong Lu; Roland Eils; Brian D Dynlacht; Itamar Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-14       Impact factor: 11.205

10.  Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway.

Authors:  Sandra Martínez; Laura Pérez; Carlos M Galmarini; Miguel Aracil; Juan C Tercero; Federico Gago; Beatriz Albella; Juan A Bueren
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.